Piramal & Ajinomoto Tie Up to Expand ADC Manufacturing Capacity

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have entered into a strategic partnership to support the development and manufacturing of antibody-drug conjugates (ADCs), an emerging class of targeted cancer therapies.

The collaboration brings together Piramal’s global manufacturing capabilities and Ajinomoto’s proprietary AJICAP technology, which enables precise, site-specific conjugation. By combining their strengths, the companies aim to offer pharmaceutical and biotech firms a more efficient path from early-stage research to commercial-scale manufacturing.

As part of the agreement, both companies will refer clients to each other based on their needs. Customers requiring advanced conjugation solutions will be directed to Ajinomoto, while those seeking contract development and manufacturing services (CDMO) will be supported by Piramal. This approach is expected to simplify the overall ADC development process.

Also Read: Aurobindo to Expand with USD 175M Biologics Unit Investment for MSD

The partnership also includes a Material Transfer Agreement, allowing Piramal to use AJICAP technology in its production processes. This move is expected to enhance precision, improve consistency, and strengthen Piramal’s role in biopharmaceutical manufacturing.

Piramal Pharma Solutions brings over two decades of experience in ADC development and a strong track record in large-scale manufacturing. The company has supported numerous programs and production batches across its global network.

Ajinomoto’s AJICAP platform is designed to improve the safety and effectiveness of ADCs by enabling better targeting of cancer cells while minimizing damage to healthy tissue. This makes it a key innovation in advancing oncology drug development.

ADCs are gaining strong momentum across the pharmaceutical sector due to their ability to deliver more precise treatments. As demand grows, partnerships like this play an important role in accelerating innovation and ensuring scalable production.

Through this collaboration, the companies aim to provide end-to-end support, helping bring next-generation therapies to market faster while improving efficiency across the value chain.